Neoplasms, Hormone-Dependent

• 

  Subject Areas on Research

  • A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. 
  • A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780. 
  • A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. 
  • A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer. 
  • Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. 
  • Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. 
  • Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. 
  • Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. 
  • Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer. 
  • Body composition, physical function and quality of life in healthy men and across different stages of prostate cancer. 
  • Breast cancer. Clinical practice guidelines in oncology. 
  • Burden of disease matters when it comes to systemic therapy for prostate cancer. 
  • Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells. 
  • Cellular and molecular studies in brain and nervous system oncology. 
  • Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. 
  • Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. 
  • Current status of endocrine therapy for metastatic breast cancer. 
  • Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. 
  • Dietary compounds in relation to dietary diversity and human health. 
  • Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer. 
  • Endocrine therapy in metastatic breast cancer. 
  • Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. 
  • Epidemiology of hormone-associated cancers as a reflection of age. 
  • Estrogen receptor determination by monoclonal antibody in fine needle aspiration breast cancer cytologies: a marker of hormone response. 
  • Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer. 
  • External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation. 
  • G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. 
  • Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. 
  • Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy. 
  • Heterogeneity in the hormonal responsiveness of clones derived from the 13762NF rat mammary tumor. 
  • Identification of an enhancer element in the estrogen receptor upstream region: implications for regulation of ER transcription in breast cancer. 
  • Improving understanding of adjuvant therapy options by using simpler risk graphics. 
  • In vivo regulation of hTERT expression and telomerase activity by androgen. 
  • Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. 
  • Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status. 
  • Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. 
  • Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? 
  • Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect. 
  • Novel chemotherapies in development for management of castration-resistant prostate cancer. 
  • On model specification and selection of the Cox proportional hazards model. 
  • PC3 is a cell line characteristic of prostatic small cell carcinoma. 
  • Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. 
  • Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. 
  • Pathology and pathophysiology of uterine smooth-muscle tumors. 
  • Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. 
  • Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. 
  • Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer. 
  • Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. 
  • Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. 
  • Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. 
  • Prostate-specific antigen as a marker of disease activity in prostate cancer. 
  • Putting Provenge in perspective. 
  • Putting Provenge in perspective. 
  • Re-induction of hormonal sensitivity in hormone-refractory prostate cancer--fact or fiction? 
  • Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. 
  • Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal. 
  • Sample size determination for comparing several survival curves with unequal allocations. 
  • Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. 
  • Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. 
  • Structural requirements for high affinity ligand binding by estrogen receptors: a comparative analysis of truncated and full length estrogen receptors expressed in bacteria, yeast, and mammalian cells. 
  • Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). 
  • Systemic therapy for prostate cancer. 
  • Teenage acne and cancer risk in US women: A prospective cohort study. 
  • The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study. 
  • Tumor characteristics in African American and white women. 
  • Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. 
• 

  Keywords of People

  • Halabi, Susan, Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics